News
MRK
139.33
-2.82%
-4.05
Merck Pulls Plug On Acquired Drug after Safety Review
Benzinga · 24m ago
Fate of Trump's new FDA commissioner nominee will fall on Senate Democrats
Seeking Alpha · 38m ago
Pfizer: The Patent Cliff Fears Are Overblown
Seeking Alpha · 1h ago
Merck says Thomas Glocer to retire from board of directors
TipRanks · 4h ago
Merck Discontinues Nemtabrutinib Program Following Review Of Phase 3 Trial Data
NASDAQ · 7h ago
Trump abandons Heidi Overton as FDA commissioner nominee: reports
Seeking Alpha · 12h ago
Merck ends development of BTK inhibitor nemtabrutinib
Seeking Alpha · 17h ago
Merck Ends Development of Blood Cancer Drug Nemtabrutinib
Dow Jones · 18h ago
Merck announces discontinuation of development program evaluating MK-1026
TipRanks · 18h ago
United States no longer considered a measles-eliminated country
Seeking Alpha · 22h ago
Merck raises dividend by 3.5% to $0.88
Seeking Alpha · 23h ago
Broker Darlings of the Dow: Merck Ranks As a Top 15 Analyst Pick
NASDAQ · 23h ago
Dow Analyst Moves: MRK
NASDAQ · 23h ago
Eli Lilly Short Interest Rises, Remains Below August Peak
Benzinga · 1d ago
Merck Announces Update on BELLWAVE Clinical Development Program Evaluating Nemtabrutinib
Barchart · 1d ago
Merck Raises Quarterly Dividend by 3.5%
Dow Jones · 1d ago
Press Release: Merck Announces First-Quarter 2027 Dividend
Dow Jones · 1d ago
*Merck Raises Quarterly Dividend to 88c From 85c >MRK
Dow Jones · 1d ago
There May Be Some Bright Spots In Merck's (NYSE:MRK) Earnings
Simply Wall St · 1d ago
Reported November 16, Roche Receives FDA Approval For Wiserdley In Combination With Everolimus For Breast Cancer Treatment
Benzinga · 1d ago
More
Webull provides a variety of real-time MRK stock news. You can receive the latest news about Merck & Co through multiple platforms. This information may help you make smarter investment decisions.
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.